๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
NCT06450067B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Active, closed
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
NCT06413745HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
59
Shanghai
2024-06-04
Recruiting
A Trail of Sperstentยฎ Used for Residual Lesions of Femoropopliteal Arteries
NCT06539689Peripheral Arterial Disease, Stenosis, Dissection
FrontAce Scientific Co., Ltd
Not applicable
240
Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nantong, Shanghai
2024-06-04
Recruiting
Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers
NCT06417086Alzheimer Disease, Cognitive Impairment
DrugDonepezil
ZhanYJ
Not applicable
176
Shanghai
2024-06-01
Recruiting
Effectiveness of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure
NCT06493292Hemodialysis Access Failure
RenJi Hospital
Observational
180
Zhengzhou, Nanjing, Shanghai
2024-06-01
Recruiting
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
NCT06889623NMIBC
Changhai Hospital
Not applicable
72
Shanghai
2024-06-01
By invitation
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
NCT06963060Gallbladder Cancer, Cholangiocarcinoma
Wei Gong
Phase 2
44
Shanghai
2024-06-01
Not yet open
LCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences
NCT06442150Type 2 Diabetes Mellitus in Obese, Type 2 Diabetes
Shanghai Municipal Hospital of Traditional Chinese Medicine
Not applicable
170
Shanghai
2024-06-01
Recruiting
A Prospective Observational Study of Perioperative Lumbar Puncture Pressure and Shunt Valve Pressure Management in Patients with Communicating Hydrocephalus Undergoing Lumboperitoneal Shunt Surgery
NCT06642129Hydrocephalus, Communicating
RenJi Hospital
Observational
30
Shanghai
2024-06-01
Not yet open
Study on the Efficacy of Long-term Drainage of Subdural Effusion After Decompressive Craniectomy
NCT06391203Traumatic Brain Injury, Decompressive Craniectomy, Subdural Effusion
RenJi Hospital
Not applicable
160
Shanghai
2024-06-01
Not yet open
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
NCT06297772AML, Adult
DrugsBusulfan·Decitabine·Fludarabine
Ruijin Hospital
Phase 3
220
Shanghai
2024-06-01
Recruiting
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
NCT06881537Locally Recurrent Colorectal Cancer
Shanghai Changzheng Hospital
Phase 2
15
Shanghai
2024-06-01
Recruiting
A Prospective Observational Study of Transcranial Doppler Ultrasound in the Assessment of Cerebral Blood Flow After Polyetheretherketone Cranioplasty
NCT06642532Cranial Defect, TCD
RenJi Hospital
Observational
10
Shanghai
2024-06-01
Recruiting
Combination of Toripalimab and JS004 Therapy for ccRCC
NCT06690697Clear Cell Renal Cell Carcinoma
DrugsJS004·Sorafenib·Axitinib·Toripalimab
Fudan University
Phase 2
80
Shanghai
2024-06-01
Recruiting
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
NCT06445803Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Rong Tao
Phase 1
48
Nanchang, Shanghai
2024-05-31
Recruiting
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
NCT07644832Hemophilia A, Hemophilia B, Factor VII Deficiency
DrugSR604
Shanghai RAAS Blood Products Co., Ltd.
Phase 1/2
76
Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an
2024-05-31
Recruiting
A Cohort Study in Newly Diagnosed MZL
NCT06449885Marginal Zone Lymphoma
Fudan University
Observational
2,500
Shanghai
2024-05-30
Recruiting
Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases
NCT06520774Aortic Arch Aneurysm, Penetrating Aortic Ulcer
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
103
Beijing, Changsha, Chengdu, Fuzhou, Hanzhou, Kunming, Nanjing, Shanghai
2024-05-30
Recruiting
A Study of GC203 TIL in Advanced Malignant Solid Tumors
NCT06375187Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer
Shanghai Juncell Therapeutics
Phase 1
18
Shanghai
2024-05-29
Recruiting
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
NCT06405425Urothelial Carcinoma
DrugsPD-1·Iza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2024-05-29
Recruiting
Expressions of Ezrin and Pip5k1ฮฑ Proteins in Airway Smooth Muscle of Asthmatic Patients
NCT06427018Asthma, Protein
Lei-Miao Yin
Observational
120
Shanghai
2024-05-28
Recruiting
The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation
NCT07314047Brain Arteriovenous Malformation, Arteriovenous Fistula
MicroPort NeuroTech Co., Ltd.
Not applicable
116
Shanghai
2024-05-28
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Beijing, Guangzhou, Hangzhou, Shanghai, Tianjin
2024-05-28
Recruiting
Prospective Clinical Trial for Children With TCRฮฑฮฒ Depleted vs Traditional Haplo Identicle HSCT
NCT06423131Graft-Versus-Host Disease, Hematopoietic Stem Cell Transplantation, Child, Only, Haploidentical Hematopoietic Stem Cell Transplantation
Sijia Gu
Not applicable
110
Shanghai
2024-05-26
Recruiting
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
NCT06458010Familial Hypercholesterolemia
RenJi Hospital
Phase EARLY_PHASE1
20
Shanghai
2024-05-24
Recruiting
Impact of External Drainage of the Main Pancreatic Duct and Common Bile Duct on Pancreatic Fistula Following Pancreaticoduodenectomy
NCT06322680Pancreaticoduodenectomy
Shanghai Zhongshan Hospital
Not applicable
322
Shanghai
2024-05-24
Recruiting
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
NCT06341556Mantle Cell Lymphoma, Maintenance Therapy
Fudan University
Phase 2
52
Shanghai
2024-05-24
Recruiting
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study
NCT06482788Esophagogastric Junction Adenocarcinoma
DrugsXelox·Adebrelimab
Ruijin Hospital
Phase 2
26
Shanghai
2024-05-22
Recruiting
Clinical Study of HIFU for Localized Prostate Cancer
NCT06362577Localized Prostate Cancer
RenJi Hospital
Observational
60
Shanghai
2024-05-21
Recruiting
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
NCT06607419B-Cell Lymphoblastic Leukemia
DrugBlinatumomab
Shanghai Jiao Tong University School of Medicine
Phase 2/3
90
Hefei, Fuzhou, Shanghai, Ningbo
2024-05-21
Recruiting
Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris
NCT06403501Acne Vulgaris
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Phase 3
692
Shanghai
2024-05-20
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Active, closed
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06328439Locally Advanced or Metastatic Solid Tumors
DrugANS014004
Avistone Biotechnology Co., Ltd.
Phase 1
40
Shanghai
2024-05-19
Recruiting
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
NCT06250972Pancreatic Adenocarcinoma
Fudan University
Phase 3
210
Shanghai
2024-05-15
Recruiting
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
NCT06541327Lymphoma, Non-Hodgkin
Ruijin Hospital
Observational
1,000
Shanghai
2024-05-15
Active, closed
A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma
NCT07155044UTUC, UC (Urothelial Cancer)
Changhai Hospital
Observational
120
Shanghai
2024-05-15
Recruiting
Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
NCT06382103Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Observational
240
Shanghai
2024-05-15
Recruiting
Thalidomide Therapy for VEOIBD
NCT06382519Inflammatory Bowel Diseases
DrugThalidomide
Children's Hospital of Fudan University
Observational
40
Shanghai
2024-05-15
Recruiting
Analysis of Deep Brain Nuclei LFP and Cortical EEG Signals During the Recovery From General Anesthesia
NCT06400901Deep Brain Stimulation Surgery, Electrophysiology, General Anesthesia, Consciousness, Loss of
Ruijin Hospital
Observational
42
Shanghai
2024-05-15
Not yet open
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)
NCT06340490Systemic Lupus Erythematosus
Guangdong Ruishun Biotech Co., Ltd
Phase 1
24
Beijing, Nanjing, Shanghai
2024-05-15
Active, closed
Phase 3 Study of ALXN1850 in Treatment-Naรฏve Pediatric Participants With HPP
NCT06079359Hypophosphatasia
DrugALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
30
Beijing, Guangzhou, Shanghai, Shenzhen
2024-05-14
Recruiting
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
NCT06427460Pancreatic Cancer
Changhai Hospital
Phase 2
67
Shanghai
2024-05-12
Recruiting
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
NCT06190275HNSCC
DrugGT201
Grit Biotechnology
Not applicable
32
Shanghai
2024-05-12
Recruiting
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
NCT06298058Advanced Solid Tumor
Shanghai Institute Of Biological Products
Phase 1
144
Shanghai
2024-05-09
Recruiting
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
NCT06455124Rectal Cancer
DrugsOxaliplatin·Capecitabine
Fudan University
Phase 2
60
Shanghai
2024-05-08
Not yet open
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
NCT06404736Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
DrugsAlbumin-Bound Paclitaxel·Carboplatin
Fudan University
Phase 2
73
Shanghai
2024-05-07
Recruiting
Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
NCT06478225Tumor Pancreas
RenJi Hospital
Not applicable
12
Shanghai
2024-05-07
Recruiting
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
NCT06446128Non-Hodgkin Lymphoma, B-cell
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1
20
Shanghai
2024-05-07
Recruiting
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
NCT06300320Chronic Graft Versus Host Disease
DrugRovadicitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
65
Hefei, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Xiangyang, Taian, Shanghai
2024-05-07
Recruiting
The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor
NCT06311968Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity
Jian Chen
Phase 2
55
Shanghai
2024-05-06
By invitation
Unique Electroencephalography (EEG) Markers of Habit Behaviors in Obsessive-Compulsive Disorder (OCD)
NCT06882902Obsessive-Compulsive Disorder
Shanghai Mental Health Center
Not applicable
35
Shanghai
2024-05-05
Recruiting
Dalpiciclib in HR+/HER2- ABC
NCT06301438Advanced Breast Cancer
DrugDalpiciclib
RenJi Hospital
Observational
103
Shanghai
2024-05-03
Recruiting
Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty
NCT04528303Diarrhea, Infantile, Enteropathy
Children's Hospital of Fudan University
Not applicable
180
Shanghai
2024-05-01
Recruiting
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
NCT06394674Non-Small Cell Lung Cancer
DrugFurmonertinib
Changhai Hospital
Phase 2
84
Shanghai
2024-05-01
Recruiting
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
NCT06368141Colon Cancer
Ruijin Hospital
Phase 2
56
Shanghai
2024-05-01
Recruiting
An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
NCT06339060Esophageal Cancer
Ruijin Hospital
Phase 3
356
Shanghai
2024-05-01
Recruiting
A Multimodal Prospective Cohort Study of Parkinsonism
NCT07553845Parkinsonism, REM Sleep Behavior Disorder
Ruijin Hospital
Observational
640
Shanghai
2024-05-01
Recruiting
Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of โ‰ค 2 cm
NCT06634979Lung Cancer (NSCLC), Lymph Node Dissection
Fudan University
Not applicable
684
Shanghai
2024-05-01
Not yet open
Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
NCT05707468Oligometastatic Prostate Carcinoma
Changhai Hospital
Not applicable
200
Guangzhou, Suzhou, Wuxi, Ningbo, Shanghai
2024-05-01
Recruiting
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
NCT065616203-year Disease-free Survival
DrugBefotertinib
Fudan University
Phase 4
592
Shanghai
2024-05-01
Recruiting
Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease
NCT06329622Chronic Kidney Disease, Sarcopenia
Huashan Hospital
Phase 3
58
Shanghai
2024-05-01
Recruiting
Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy
NCT06738888Thyroid Cancer, Thyroid Diseases, Thyroid Nodule
Shanghai 6th People's Hospital
Observational
300
Shanghai
2024-05-01
Recruiting
Research on Body Voice AI Recognition System for Children's Health Management
NCT06542120Congenital Heart Disease, Bronchopneumonia, Abdominal Disease
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
30,000
Wuhan, Changsha, Shanghai, Kunming
2024-05-01
Not yet open
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer
NCT06423937Colorectal Cancer
DrugCamrelizumab
Fudan University
Phase 2
129
Shanghai
2024-05
Recruiting
Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients
NCT06404697Breast Cancer
Ruijin Hospital
Phase 2
24
Shanghai
2024-05
Not yet open
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
NCT06370754Pancreatic Cancer
DrugsJS015·JS007·JS004·Irinotecan liposome
Fudan University
Phase 1/2
117
Shanghai
2024-04-30
Recruiting
The Effect of Morning vs Evening Aerobic Exercise Training on Cardiac Remodeling and Function Improvement in Patients After ST Elevation Myocardial Infarction
NCT06385834ST-segment Elevation Myocardial Infarction (STEMI)
RenJi Hospital
Not applicable
201
Shanghai
2024-04-30
Recruiting
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385925Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai
2024-04-29
Recruiting
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
NCT06389006Breast Cancer
DrugsEpirubicin·Disitamab Vedotin·Toripalimab·Cyclophosphamide
RemeGen Co., Ltd.
Phase 2
79
Shanghai
2024-04-29
Recruiting
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
NCT06332170Advanced Solid Tumor
DrugsHS-20093·Cisplatin/carboplatin·Enzalutamide·Cetuximab
Hansoh BioMedical R&D Company
Phase 1
610
Shanghai
2024-04-26
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLY3650150
Eli Lilly and Company
Phase 3
450
Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai
2024-04-26
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Recruiting
The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
NCT06479317Immune Thrombocytopenia With Positive ANA Antibodies
Yunfeng Cheng
Not applicable
129
Shanghai
2024-04-24
Recruiting
The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP
NCT06479304Immune Thrombocytopenia With Positive ANA Antibodies
Yunfeng Cheng
Not applicable
129
Shanghai
2024-04-24
Recruiting
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
NCT06439771Locally Advanced or Metastatic Breast Cancer
DrugYL202 should be infused
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
180
Shanghai
2024-04-23
Active, closed
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Osteogenesis Imperfecta
DrugRomosozumab
Amgen
Phase 3
111
Beijing, Shenzhen, Wuhan, Suzhou, Changchun, Jinan, Chengdu, Shanghai
2024-04-22
Recruiting
Natural Course and Therapeutic Effect of Recurrent Acute Pancreatitis
NCT06355206Cohort Study, Recurrent Acute Pancreatitis
Changhai Hospital
Observational
2,000
Shanghai
2024-04-22
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Paclitaxel·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 1/2
287
Beijing, Cheng Du Shi, Linyi, Shanghai, Wuhan
2024-04-22
Recruiting
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
NCT06269211Carcinoma, Non-Small-Cell Lung
Ruijin Hospital
Phase 2
29
Guangzhou, Shanghai
2024-04-20
Active, closed
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
NCT06356597Colorectal Cancer
Jing-yuan Fang, MD, Ph. D
Phase 2
33
Shanghai
2024-04-19
Recruiting
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
NCT06375473Pancreatic Cancer
DrugIrinotecan liposome II combination therapy
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Beijing, Changsha, Cheng Du Shi, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2024-04-18
Recruiting
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion
NCT06211712Acute Ischemic Stroke
Huashan Hospital
Not applicable
120
Shanghai
2024-04-17
Recruiting
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
NCT06258642Small Cell Lung Cancer Recurrent
DrugsIrinotecan liposome·Anlotinib
Fudan University
Not applicable
39
Shanghai
2024-04-17
Active, closed
A Study of MHB039A for Advanced Solid Tumor
NCT06345482Advanced Solid Tumor
DrugMHB039A
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
196
Shanghai
2024-04-16
Recruiting
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
NCT06365671B-cell Non Hodgkin Lymphoma
DrugsRelma-cel·Relmacabtagene Autoleucel
Ruijin Hospital
Phase 2
16
Shanghai
2024-04-16
Recruiting
Phenotype and Multi-omics Analysis of Children With Congenital Diarrhea and Enteropathy in China
NCT06356545Diarrhea Infantile
Children's Hospital of Fudan University
Observational
60
Shanghai
2024-04-15
Active, closed
Toripalimab Combined With SBRT for NSCLC
NCT06293690Non-small Lung Cancer
DrugsSBRT·Toripalimab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
40
Shanghai
2024-04-15
Recruiting
Efficacy and Mechanism of Augmentation of Cognitive Behavioral Therapy With Transcranial Alternating Current Stimulation(tACS) for Obsessive-Compulsive Disorder (OCD)
NCT06717165Obsessive Compulsive Disorder (OCD)
Shanghai Mental Health Center
Not applicable
62
Shanghai
2024-04-15
Recruiting
PEELED INTERNAL LIMITING MEMBRANE REPOSITION
NCT06359548Macular Holes
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
90
Shanghai
2024-04-15
Recruiting
A Cohort Study on Early Stages of Heart Failure
NCT06673615Stages of Heart Failure
Shanghai East Hospital
Observational
8,000
Shanghai
2024-04-15
Active, closed
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
NCT06485219Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
DrugPurinostat Mesylate
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
50
Shanghai, Chengdu
2024-04-14
Recruiting
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
NCT06336707Advanced Solid Tumors
DrugsHS-20089·Cisplatin/carboplatin·Adebrelimab·Bevacizumab
Hansoh BioMedical R&D Company
Phase 1
1,048
Shanghai
2024-04-11
Recruiting
Lymph Node Pathologic Grading Strategy
NCT06745830Lung Adenocarcinoma
Fudan University
Observational
2,998
Shanghai
2024-04-10
Recruiting
Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets
NCT06966635Hyperuricemia or Gout, Nephrolithiasis
DrugSodium bicarbonate
Huashan Hospital
Phase 4
312
Shanghai
2024-04-10
Recruiting
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
NCT06402708Thymic Carcinoma
Fudan University
Phase 3
172
Shanghai
2024-04-09
Not yet open
Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma
NCT06368934Glioma, Glioblastoma
Huashan Hospital
Not applicable
326
Shanghai
2024-04-08
Recruiting
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456CLL/SLL
DrugsChlorambucil·Lisaftoclax·Acalabrutinib·Fludarabine
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Recruiting
A First-ever Research Collaboration to Characterize MRI Measured Neural Flexibility Development in Chinese Toddlers
NCT04916652Growth & Development, Brain
Sociรฉtรฉ des Produits Nestlรฉ (SPN)
Observational
60
Shanghai
2024-04-06
Rows per page Showing 2501–2600 of 3827
Previous 24 25 26 27 28 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=26

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.